A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

NCT05975073 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

MTAP-null Non-Small-Cell Lung Cancer
MTAP-null Solid Tumors

Interventions

DRUG: Anvumetostat
DRUG: IDE397

Sponsor

Amgen